

	September 30, 2017	December 31, 2016
	€ 1,000	€ 1,000
Assets		
Current assets		
Cash and cash equivalents	39,742	59,200
Prepayments and other receivables	2,283	2,420
Social securities and other taxes	777	395
Total current assets	42,802	62,015
Property, plant and equipment	2,740	3,438
Intangible assets	52	90
Total assets	45,594	65,543
Equity and liabilities		
Equity		
Equity attributable to owners of the Company	32,749	53,136
Non-controlling interests	(10)	--
Total equity	32,739	53,136
Current liabilities		
Trade payables	250	328
Social securities and other taxes	314	312
Pension premiums	34	13
Deferred income	657	--
Other current liabilities	5,117	6,057
Total current liabilities	6,372	6,710
Borrowings	6,483	5,697
Total liabilities	12,855	12,407
Total equity and liabilities	45,594	65,543

The notes are an integral part of these condensed consolidated financial statements.

	Three month period ended September 30,		Nine month period ended September 30,	
	2017	2016	2017	2016
	€ 1,000	€ 1,000	€ 1,000	€ 1,000
Other income	326	447	984	1,725
Research and development costs	(7,226)	(8,319)	(22,808)	(23,823)
General and administrative costs	(2,753)	(2,001)	(7,949)	(7,218)
Total operating costs	(9,979)	(10,320)	(30,757)	(31,041)
Operating result	(9,653)	(9,873)	(29,773)	(29,316)
Finance income and expense	(868)	(254)	(2,589)	(968)
Result before corporate income taxes	(10,521)	(10,127)	(32,362)	(30,284)
Income taxes	--	--	(2)	--
Result for the period	(10,521)	(10,127)	(32,364)	(30,284)
Other comprehensive income	49	--	114	--
Total comprehensive income (attributable to owners of the Company)	(10,472)	(10,127)	(32,250)	(30,284)
Result attributable to				
Owners of the Company	(10,511)	(10,127)	(32,354)	(30,284)
Non-controlling interests	(10)	--	(10)	--
	(10,521)	(10,127)	(32,364)	(30,284)
Share information				
Weighted average number of shares outstanding ¹	25,282,588	23,346,856	24,255,792	23,346,390
Earnings per share attributable to owners of the Company (expressed in Euro per share)				
Basic loss per share¹	(0.42)	(0.43)	(1.33)	(1.30)
Diluted loss per share¹	(0.42)	(0.43)	(1.33)	(1.30)

The notes are an integral part of these condensed consolidated financial statements.

1. For this period presented in these financial statements, the potential exercise of share options is not included in the diluted earnings per share calculation as the Company was loss-making in all periods. Due to the anti-dilutive nature of the outstanding options, basic and diluted earnings per share are equal in this period.

PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Changes in Equity

	Attributable to owners of the Company								
	Number of shares	Share Capital	Share Premium	Equity Settled Employee Benefit Reserve	Translation Reserve	Accumulated Deficit	Total	Non-controlling interests	Total Equity
	€ 1,000	€ 1,000	€ 1,000	€ 1,000	€ 1,000	€ 1,000	€ 1,000	€ 1,000	€ 1,000
Balance at January 1, 2016	23,345,965	934	123,595	1,899	1	(36,630)	89,799	--	89,799
Result for the period	--	--	--	--	--	(30,284)	(30,284)	--	(30,284)
Other comprehensive income	--	--	--	--	0	--	0	--	0
Recognition of share-based payments	--	--	--	1,917	--	--	1,917	--	1,917
Share options exercised	891	0	2	--	--	--	2	--	2
Balance at September 30, 2016	23,346,856	934	123,597	3,816	1	(66,914)	61,434	--	61,434
Balance at January 1, 2017	23,346,856	934	123,597	4,353	(15)	(75,733)	53,136	--	53,136
Result for the period	--	--	--	--	--	(32,354)	(32,354)	(10)	(32,364)
Other comprehensive income	--	--	--	--	114	--	114	--	114
Recognition of share-based payments	--	--	--	3,090	--	--	3,090	--	3,090
Shares issued in the period	2,115,612	85	8,677	--	--	--	8,762	0	8,762
Share options exercised	381	0	1	--	--	--	1	--	1
Balance at September 30, 2017	25,462,849	1,019	132,275	7,443	99	(108,087)	32,749	(10)	32,739

The notes are an integral part of these condensed consolidated financial statements.

PROQR THERAPEUTICS N.V.
Unaudited Condensed Consolidated Statement of Cash Flows

	Three month period ended September 30,		Nine month period ended September 30,	
	2017	2016	2017	2016
	€ 1,000	€ 1,000	€ 1,000	€ 1,000
Cash flows from operating activities				
Net result	(10,472)	(10,127)	(32,250)	(30,284)
Adjustments for:				
— Depreciation	267	284	807	978
— Share-based compensation	890	628	3,090	1,917
— Financial income and expenses	868	254	2,589	968
Changes in working capital	829	(1,843)	(539)	(551)
<i>Cash used in operations</i>	<i>(7,618)</i>	<i>(10,804)</i>	<i>(26,303)</i>	<i>(26,972)</i>
Corporate income tax paid	--	--	(2)	--
Interest received/(paid)	10	11	69	77
Net cash used in operating activities	(7,608)	(10,793)	(26,236)	(26,895)
Cash flow from investing activities				
Purchases of intangible assets	--	--	--	--
Purchases of property, plant and equipment	(18)	(422)	(111)	(2,495)
Net cash used in investing activities	(18)	(422)	(111)	(2,495)
Cash flow from financing activities				
Proceeds from issuance of shares, net of transaction costs	5,539	--	8,762	--
Proceeds from exercise of share options	--	--	1	2
Proceeds from borrowings	100	--	201	193
Proceeds from convertible loans	150	--	150	--
Redemption of financial lease	--	--	--	(15)
Net cash generated by financing activities	5,789	--	9,114	180
Net increase/(decrease) in cash and cash equivalents	(1,837)	(11,215)	(17,233)	(29,210)
Currency effect cash and cash equivalents	(742)	(175)	(2,225)	(734)
Cash and cash equivalents, at beginning of the period	42,321	76,311	59,200	94,865
Cash and cash equivalents at the end of the period	39,742	64,921	39,742	64,921

The notes are an integral part of these condensed consolidated financial statements.